Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pharmaxis Ltd ( (AU:SNT) ) has issued an announcement.
Syntara Limited announced a proposal to issue zero exercise priced options (ZEPOs) to its Chief Executive Officer as part of his remuneration package, replacing a portion of his cash salary. This initiative, pending shareholder approval at the 2025 annual general meeting, reflects a strategic move to incentivize the CEO’s performance and align his interests with the company’s long-term success. The ZEPOs will vest in June 2026, with trading restrictions on the shares until 2030, indicating a focus on long-term growth and stability.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited operates in the pharmaceutical industry, focusing on developing innovative treatments and solutions. The company is engaged in creating and managing employee incentive schemes to align the interests of its executives with company performance.
Average Trading Volume: 11,218,662
Technical Sentiment Signal: Sell
Current Market Cap: A$82.87M
See more data about SNT stock on TipRanks’ Stock Analysis page.